` LQDA (Liquidia Corp) vs S&P 500 Comparison - Alpha Spread

LQDA
vs
S&P 500

Over the past 12 months, LQDA has significantly outperformed S&P 500, delivering a return of +202% compared to the S&P 500's +13% growth.

Stocks Performance
LQDA vs S&P 500

Loading
LQDA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
LQDA vs S&P 500

Loading
LQDA
S&P 500
Difference
www.alphaspread.com

Performance By Year
LQDA vs S&P 500

Loading
LQDA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Liquidia Corp vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Liquidia Corp
Glance View

Market Cap
3B USD
Industry
Pharmaceuticals

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.

LQDA Intrinsic Value
33.24 USD
Overvaluation 3%
Intrinsic Value
Price
Back to Top